Salidroside, a golden-root plant compound sold as a purified dietary supplement, is taken to raise resilience to physical and mental stress. Its longevity promise rests on animal and cell evidence; human evidence for the pure compound is thin. Short-term use appears well tolerated. Open risks are largely theoretical: added bleeding tendency with clot-preventing medication, extra sugar lowering with diabetes medication, and no information on pregnancy or years of use. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 70–99 mg/dL | Safety check: additive glucose lowering with diabetes drugs |
| HbA1c | 4.0–5.6% | Safety check: tracks average glucose when combined with diabetes drugs |
| INR | 0.8–1.2 (warfarin users: prescriber's target range) | Safety check: bleeding risk with warfarin |
| Serum creatinine | 0.6–1.3 mg/dL | Safety check: reduced kidney clearance raises salidroside exposure |
Cadence: Baseline before starting; INR at 1–2 weeks for warfarin users; fasting glucose at 2 weeks for people on glucose-lowering drugs; all laboratory markers at 3 months, then every 6–12 months during continued use